Literature DB >> 29215902

Words matter: Implementing the electronically activated recorder in schizotypy.

Kyle S Minor1, Beshaun J Davis1, Matthew P Marggraf1, Lauren Luther1, Megan L Robbins2.   

Abstract

In schizophrenia-spectrum populations, analyzing the words people use has offered promise for unlocking information about affective states and social behaviors. The electronically activated recorder (EAR) is an application-based program that is combined with widely used smartphone technology to capture a person's real-world interactions via audio recordings. It improves on the ecological validity of current methodologies by providing objective and naturalistic samples of behavior. This study is the first to implement the EAR in people endorsing elevated traits of schizophrenia-spectrum personality disorders (i.e., schizotypy), and we expected the EAR to (a) differentiate high and low schizotypy groups on affective disturbances and social engagement and (b) show that high schizotypy status moderates links between affect and social behavior using a multimethod approach. Lexical analysis of EAR recordings revealed greater negative affect and decreased social engagement in those high in schizotypy. When assessing specific traits, EAR and ecological momentary assessment (EMA) converged to show that positive schizotypy predicted negative affect. Finally, high schizotypy status moderated links between negative affect and social engagement when the EAR was combined with EMA. Adherence did not influence results, as both groups wore the EAR more than 90% of their waking hours. Findings supported using the EAR to assess real-world expressions of personality and functioning in schizotypy. Evidence also showed that the EAR can be used alongside EMA to provide a mixed-method, real-world assessment that is high in ecological validity and offers a window into the daily lives of those with elevated traits of schizophrenia-spectrum personality disorders. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Year:  2017        PMID: 29215902     DOI: 10.1037/per0000266

Source DB:  PubMed          Journal:  Personal Disord        ISSN: 1949-2723


  7 in total

1.  Social functioning in schizotypy: How affect influences social behavior in daily life.

Authors:  Kyle S Minor; Kathryn L Hardin; Danielle M Beaudette; Lesley C Waters; Anna L White; Virgilio Gonzenbach; Megan L Robbins
Journal:  J Clin Psychol       Date:  2020-07-02

2.  A test of the cognitive model of negative symptoms: Associations between defeatist performance beliefs, self-efficacy beliefs, and negative symptoms in a non-clinical sample.

Authors:  Lauren Luther; George M Coffin; Ruth L Firmin; Kelsey A Bonfils; Kyle S Minor; Michelle P Salyers
Journal:  Psychiatry Res       Date:  2018-08-16       Impact factor: 3.222

3.  Personalizing interventions using real-world interactions: Improving symptoms and social functioning in schizophrenia with tailored metacognitive therapy.

Authors:  Kyle S Minor; Matthew P Marggraf; Beshaun J Davis; Jessica L Mickens; Danielle B Abel; Megan L Robbins; Kelly D Buck; Sarah E Wiehe; Paul H Lysaker
Journal:  J Consult Clin Psychol       Date:  2021-08-19

4.  Expanding the positivity offset theory of anhedonia to the psychosis continuum.

Authors:  Marcel Riehle; Matthias Pillny; Tania M Lincoln
Journal:  Schizophrenia (Heidelb)       Date:  2022-05-03

5.  Social functioning in schizophrenia: Comparing laboratory-based assessment with real-world measures.

Authors:  Danielle B Abel; Kyle S Minor
Journal:  J Psychiatr Res       Date:  2021-04-30       Impact factor: 5.250

6.  Quality versus quantity: Determining real-world social functioning deficits in schizophrenia.

Authors:  Danielle B Abel; Michelle P Salyers; Wei Wu; Mahogany A Monette; Kyle S Minor
Journal:  Psychiatry Res       Date:  2021-05-01       Impact factor: 11.225

7.  The link between formal thought disorder and social functioning in schizophrenia: A meta-analysis.

Authors:  Matthew P Marggraf; Paul H Lysaker; Michelle P Salyers; Kyle S Minor
Journal:  Eur Psychiatry       Date:  2020-03-23       Impact factor: 5.361

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.